The latest biotech news

News and Trends 17 Mar 2023

How cancer cells repair DNA damage from radiotherapy

A team of scientists led by Kei-ichi Takata from the Center for Genomic Integrity (CGI) within the Institute for Basic Science (IBS) in South Korea, has discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. Ionizing radiation (IR) therapy is frequently used in the treatment […]

March 17, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 16 Mar 2023

Inspire Biotherapeutics launches to target lung diseases through gene therapy

Inspire Biotherapeutics Inc., an emerging Canadian biotech company with a mission to create gene therapies for monogenic and acquired diseases of the lung, is set to move its novel lung tropic AAV gene therapy into clinical validation. The AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types […]

March 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 16 Mar 2023

Mediar Therapeutics boosts fibrosis portfolio with $105M financing

Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, has announced a $105 million financing. This includes a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol […]

March 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 15 Mar 2023

Nanite receives funding to deliver genetic therapies to the lungs

Nanite Inc. has announced an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung. This builds on the $6 million seed financing recently announced by the company. One of the most significant challenges in developing new therapies for patients with cystic fibrosis is effective drug […]

March 15, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 15 Mar 2023

Cambrian Bio to boost aging pipeline with Amplifier Therapeutics launch

Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, has launched its new pipeline company, Amplifier Therapeutics. The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. Amplifier has also acquired Betagenon AB, a Swedish biopharmaceutical company, which has discovered novel AMPK activators. It will continue its work […]

March 15, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Mar 2023

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and commercializes cancer medicines. The boards of directors of both companies have unanimously approved the transaction. “Pfizer is deploying its financial resources to […]

March 14, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 14 Mar 2023

Astellas menopause study meets endpoints but leukemia drug disappoints

There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor […]

March 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 14 Mar 2023

How the microbiome can predict cancer immunotherapy success

A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team headed by Eran Elinav of the Cancer & Microbiome Division of the German Cancer Research Center (DKFZ), and led by Christoph Stein-Thoeringer, professor of Clinical Infectiology and Translational Microbiome Research at the Medical Faculty of […]

March 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Mar 2023

Calliditas shares rise as phase 3 endpoints met in kidney disease trial

Swedish company Calliditas Therapeutics AB has announced positive topline results from the global, randomized, double-blind, placebo-controlled phase 3 clinical trial investigating the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). Calliditas share prices rose 30% in the aftermath of the announcement. IgAN, or Berger’s disease, is […]

March 14, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 13 Mar 2023

New therapy for prevention and treatment of COVID-19

ExeVir Bio, and its scientific founders at Belgium’s VIB, Flanders’ leading life sciences institute, have published a pre-print paper by De Cae et al., entitled “Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane-proximal epitope of the spike.” Nearly all SARS-CoV-2 neutralizing antibodies used in the clinic show substantial loss of potency against the […]

March 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 13 Mar 2023

Sanofi adds diabetes drug through Provention Bio $2.9B acquisition

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds […]

March 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Mar 2023

Twisted blood vessels reveal cancer treatment success potential

Picture Health has announced plans to commercialize a new artificial intelligence (AI)-powered biomarker with the potential to transform the way doctors decide how to treat cancer. The advancement in cancer outcomes research sheds new light on cancer tumors: analyzing the state of the blood vessels that feed them. Recently published studies have shown the technology […]

March 9, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

How cancer cells repair DNA damage from radiotherapy

Inspire Biotherapeutics launches to target lung diseases through gene therapy

Mediar Therapeutics boosts fibrosis portfolio with $105M financing

Nanite receives funding to deliver genetic therapies to the lungs

Cambrian Bio to boost aging pipeline with Amplifier Therapeutics launch

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Astellas menopause study meets endpoints but leukemia drug disappoints

How the microbiome can predict cancer immunotherapy success

Calliditas shares rise as phase 3 endpoints met in kidney disease trial

New therapy for prevention and treatment of COVID-19

Sanofi adds diabetes drug through Provention Bio $2.9B acquisition

Twisted blood vessels reveal cancer treatment success potential

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!